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Motivation: Lung cancer is the leading cause of cancer
death, and lung adenocarcinoma (LUAD) is its pre-
dominant histological subtype. Fifteen single nucleotide
polymorphisms (SNPs) have been signiﬁcantly associ-
ated with LUAD risk in genome-wide association
studies (GWAS). However, because most GWAS SNPs
reside in non-coding regions and are co-inherited with
hundreds of SNPs in linkage disequilibrium (LD), which
SNPs play a causal role in disease development remains
largely unknown. We hypothesized that some of these
SNPs affect oncogenic transcriptional programs by
modulating the activity of gene enhancers in alveolar
epithelial cells (AECs), the purported cells of origin for
LUAD.
Methods: To test this hypothesis, we overlaid epigenomic
features of primary human AECs over the locations of in-
dex LUAD risk SNPs and associated high LD SNPs. Lucif-
erase assays for enhancer activity were performed for
candidate SNPs that were predicted to disrupt transcrip-
tion factor (TF) binding sites in loci marked by features of
active enhancers. Expression quantitative trait loci (eQTL)
analysis was also performed using The Cancer Genome
Atlas (TCGA) dataset and the online Genotype-Tissue
Expression (GTEx) Portal to identify potential target genes
of each SNP-enhancer pair.
Results: Thirty-three LUAD risk-associated SNPs map-
ped to putative AEC enhancer regions. TF binding site
prediction suggests that numerous SNPs might alter the
binding afﬁnity of TFs implicated in lung cancer,
including RXRA and NKX2-1. Luciferase assays indicate
that two of the SNPs signiﬁcantly affect enhancer activity
in lung cancer cell lines. eQTL analyses link each of the
putative enhancers to candidate target genes, including
both known oncogenes and genes not previously asso-
ciated with lung cancer.
Conclusions: Taken together, our analyses provide new
mechanistic insight into long-known associations be-
tween non-coding SNPs and LUAD outcomes, and may
ultimately yield more effective and personalized strate-
gies for lung cancer risk assessment, prevention, and
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Non-small cell lung cancer (NSCLC) is the leading cause for
cancer related mortality rates in the US, often associated
with 20-35% response rate and a w10 month median
survival time. Currently, tissue diagnostics is performed
using immunohistochemistry, FISH, and PCR for staging
and treatment planning. In vivo imaging such as PET or CT
is also used to detect the severity of NSCLC. NSCLC
metastasize by spreading primary tumor cells to distant
organs. Therefore, it is possible to isolate circulating tu-
mor cells (CTC) in patients’ blood, and as the cells origi-
nate from tumor, detailed genetic evaluation about the
tumor could be performed. Isolation and study on circu-
lating tumor cells is slowly evolving as liquid biopsy of
cancer. In fact, CTC detection technique is emerging as
prognostic markers to identify treatment response in
NSCLC patients. The current CTC capture methodology
involves cell search technologies, predominantly relying
on EpCAM expression based detection. However with the
discovery of tumor heterogeneity and consequent impact
on clinical treatment, it is important to detect patients
with CTCs early on, based on their genetic alterations.
BothHER2 (2-5%mutation incidence) andEGFR (10-35%
mutation incidence) overexpression have been pro-
nounced in patient biopsies and their exclusivity in in-
dividuals has been seen as a prerequisite in
chemotherapeutic selection and dose. Moreover there is
no standardized process to selectively identify CTCs based
on HER2 and EGFR surface expressions. While EGFR and
resistant mutations has been prominent, in the under-
standing ofNSCLC characterization, HER2 is relatively less
explored and frequently associated with breast cancer
detection. Recent studies show that HER2 expressions
correlate with metastases and disease free survival.
Overall this fact leads us to believeHER2markers could be
present in CTCs. Therefore, we are developing magnetic
iron nanocubes (FeNC) functionalized with either Her-
ceptin or Cetuximab as markers. These CTC markers can
be correlated with tumor heterogeneity and decide ther-
apeutic targets forﬁrst line and second line treatment. Our
approach involves cell sensing using magnetic nano-
particles (MNP), counting and subsequent separation of
live A549 (HER2þve; EGFRþve) and HCC827 (HER2 -ve;
EGFRþve) cells from a mixture for further processing. In
our current work we have synthesized HER2 and EGFR
receptor targeting iron oxide nanoparticles (50nm) that
